Search by Drug Name or NDC
NDC 00023-3921-02 BOTOX 200 [USP'U]/1 Details
BOTOX 200 [USP'U]/1
BOTOX is a INTRADERMAL; INTRAMUSCULAR INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Allergan, Inc.. The primary component is BOTULINUM TOXIN TYPE A.
Product Information
| NDC | 00023-3921 |
|---|---|
| Product ID | 0023-3921_b1bbf0e3-3d1b-4b7b-89f4-d59c872f8585 |
| Associated GPIs | 74400020052140 |
| GCN Sequence Number | 065890 |
| GCN Sequence Number Description | onabotulinumtoxinA VIAL 200 UNIT INJECTION |
| HIC3 | S7A |
| HIC3 Description | NEUROMUSCULAR BLOCKING AGENTS |
| GCN | 28011 |
| HICL Sequence Number | 004867 |
| HICL Sequence Number Description | ONABOTULINUMTOXINA |
| Brand/Generic | Brand |
| Proprietary Name | BOTOX |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | onabotulinumtoxinA |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
| Route | INTRADERMAL; INTRAMUSCULAR |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | [USP'U]/1 |
| Substance Name | BOTULINUM TOXIN TYPE A |
| Labeler Name | Allergan, Inc. |
| Pharmaceutical Class | Acetylcholine Release Inhibitor [EPC], Acetylcholine Release Inhibitors [MoA], Neuromuscular Blockade [PE], Neuromuscular Blocker [EPC] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA103000 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00023-3921-02 (00023392102)
| NDC Package Code | 0023-3921-02 |
|---|---|
| Billing NDC | 00023392102 |
| Package | 1 VIAL in 1 CARTON (0023-3921-02) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL |
| Marketing Start Date | 2010-01-11 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |